Skip NavigationSkip to Content
Return Return to Search Results

CpG oligodeoxynucleotides allow for effective adoptive T-cell therapy in chronic retroviral infection

  1. Author:
    Kraft, A. R. M.
    Krux, F.
    Schimmer, S.
    Ohlen, C.
    Greenberg, P. D.
    Dittmer, U.

  2. Author Address

    Univ Duisburg Essen, Inst Virol, Essen, Germany. NCI, SAIC, Frederick, MD 21701 USA. Univ Washington, Dept Med & Immunol, Seattle, WA 98195 USA.;Dittmer, U, Univ Duisburg Essen, Inst Virol, Essen, Germany.;ulf.dittmer@uni-due.de
    1. Year: 2007
    2. Date: Apr
  2. Journal: Blood
    1. 109
    2. 7
    3. Pages: 2982-2984
  4. Type of Article: Article
  5. ISSN: 0006-4971
  1. Abstract:

    Adoptive T-cell therapy in cancer or chronic viral infections is often impeded by the development of functional impairment of the transferred cells. To overcome this therapeutic limitation we combined adoptive transfer of naive, virus-specific CD8(+) T cells with immunostimulative CpG oligodeoxynucleotides (ODNs) in mice chronically infected with the Friend retrovirus. The CpG-ODN co-injection prevented the T cells from developing functional defects in IFN gamma and granzyme production and degranulation of cytotoxic molecules. Thus, the transferred T cells were able to reduce chronic viral loads when combined with CpG-ODNs. This strategy provides a new approach for developing successful adoptive T-cell therapy against chronic infections.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1182/blood-2006-06-022178
  3. View record in Web of Science®
  4. WOS: 000245639000052

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel